Physician profile
Steven Rivas
NPI 1164550307
$10,377.02
in general payments reported to CMS, 2019-2025
15 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,460 · 2020: $489 · 2021: $767 · 2022: $913 · 2023: $387 · 2024: $908 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,798.23 | 2019-2024 | Assurity, Gallant |
| Medtronic Vascular, INC. | $2,226.01 | 2019-2020 | |
| Medtronic, INC. | $2,018.03 | 2019-2025 | Symplicity G3 |
| Boston Scientific Corporation | $840.47 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Opticross |
| Janssen Pharmaceuticals, INC | $631.11 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $454.44 | 2019-2024 | Lifevest |
| Pbg Puerto Rico LLC | $392.67 | 2019-2023 | |
| Amgen INC. | $321.51 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $217.80 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $181.53 | 2021-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.46 | 2022-2025 | Jardiance |
| Cordis US Corp. | $57.95 | 2024 | Mynx Control |
| Merck Sharp & Dohme LLC | $36.67 | 2021-2022 | |
| Pfizer Pharmaceuticals LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.